Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
| ▸ | CPA1 | P15085 | 2/20 | 0.30 |
| ▸ | CPB1 | P15086 | 1/20 | 0.30 |
| ▸ | CPA3 | P15088 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799248 | 0.72 | MAOA (0.39) | MAOAMAOB | |
| SCHEMBL1025157 | 0.69 | MME (0.42) | CPA1MME | |
| SCHEMBL17509396 | 0.67 | ANPEP (0.36) | — | |
| SCHEMBL22444457 | 0.65 | RIPK1 (0.42) | — | |
| SCHEMBL22444765 | 0.65 | RIPK1 (0.42) | — | |
| SCHEMBL22444522 | 0.65 | RIPK1 (0.42) | — | |
| SCHEMBL22444535 | 0.65 | RIPK1 (0.42) | — | |
| SCHEMBL22444558 | 0.64 | RIPK1 (0.43) | — | |
| SCHEMBL28103077 | 0.64 | CYP1A2 (0.36) | TRPA1CPA1CPB1CPA3CPB2 | |
| SCHEMBL688821 | 0.63 | KEAP1 (0.39) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0391893-B1 | POROUS MICROSPHERES FOR DRUG DELIVERY AND METHODS FOR MAKING SAME | The University of Kentucky Research Foundation (US) | 1993-08-25 | — | — | EP | claimed |
| EP-0391893-A1 | POROUS MICROSPHERES FOR DRUG DELIVERY AND METHODS FOR MAKING SAME. | UNIV KENTUCKY RES FOUND (US) | 1990-10-17 | — | — | EP | claimed |
| WO-1989005632-A1 | POROUS MICROSPHERES FOR DRUG DELIVERY AND METHODS FOR MAKING SAME | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1989-06-29 | — | — | WO | claimed |
| US-4818542-A | POLYMER NETWORK CONTAINING ACTIVE MATERIALS FOR CONTROLLED RELEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1989-04-04 | — | — | US | claimed |
| EP-3883606-B9 | SAFE AND EFFECTIVE METHOD OF TREATING ULCERATIVE COLITIS WITH ANTI-IL12/IL23 ANTIBODY | JANSSEN BIOTECH INC (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118251413-A | Methods of treating Crohn's disease with anti-IL 23 specific antibodies | 詹森生物科技公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240199733-A1 | Anti-IL-23 Antibodies | JANSSEN BIOTECH INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199734-A1 | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody | JANSSEN BIOTECH, INC. | 2024-06-20 | — | — | US | disclosed |
| CN-112218885-B | VCAR compositions and methods of use | 波赛达治疗公司 | 2024-06-18 | — | — | CN | disclosed |
| US-12011480-B2 | Nanoparticle compositions for sustained therapy | UTI LIMITED PARTNERSHIP (CA) | 2024-06-18 | — | — | US | disclosed |
| US-20240182557-A1 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | JANSSEN BIOTECH INC (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024110898-A1 | METHOD OF TREATING ULCERATIVE COLITIS WITH ANTI-IL23 SPECIFIC ANTIBODY | JANSSEN BIOTECH, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-0391893-B1 | POROUS MICROSPHERES FOR DRUG DELIVERY AND METHODS FOR MAKING SAME | The University of Kentucky Research Foundation (US) | 1993-08-25 | — | — | EP | disclosed |
| EP-0541549-A1 | BIODEGRADABLE POLYMERIC MATERIALS AND ARTICLES FABRICATED THEREFROM | AlliedSignal Inc. (US) | 1993-05-19 | — | — | EP | disclosed |
| EP-0467389-A2 | Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1992-01-22 | — | — | EP | disclosed |
| WO-1991006681-A1 | METHOD FOR ENHANCING THE BIODEGRADATION OF BIODEGRADABLE POLYMERIC MATERIALS AND OF ARTICLES FABRICATED THEREFROM | ALLIED-SIGNAL INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| WO-1991006601-A1 | BIODEGRADABLE POLYMERIC MATERIALS AND ARTICLES FABRICATED THEREFROM | ALLIED-SIGNAL INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| EP-0391893-A1 | POROUS MICROSPHERES FOR DRUG DELIVERY AND METHODS FOR MAKING SAME. | UNIV KENTUCKY RES FOUND (US) | 1990-10-17 | — | — | EP | disclosed |
| WO-1989005632-A1 | POROUS MICROSPHERES FOR DRUG DELIVERY AND METHODS FOR MAKING SAME | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1989-06-29 | — | — | WO | disclosed |
| US-4818542-A | POLYMER NETWORK CONTAINING ACTIVE MATERIALS FOR CONTROLLED RELEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1989-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12011480-B2 | Nanoparticle compositions for sustained therapy | CD4, CD47, MALT1 | NR4A2 385/4885TRPA1 4052/4885FOLH1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.